Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV

References

• Lee GM, Gortmaker SL, McIntosh K, Hughes MD, Oleske JM. Quality of life for children and adolescents: Impact of HIV infection and antiretroviral treatment. Pediatrics. 2006;117(2):273–283.
   PubMed Web of Science ®Google Scholar
• Storm DS, Boland MG, Gortmaker SL, et al. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics. 2005;115(2): e173–e182.
   PubMed Web of Science ®Google Scholar
• Butler A, Williams P, Howland L, Hutton A, Storm D, Seage GR III. Disclosure of HIV infection status and health-related quality of life in children with HIV infection. Pediatrics. 2009;123(3):935–943.
   PubMed Web of Science ®Google Scholar
• Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. July 29, 2008; pp 1–134. Available from: http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed May 1, 2010.
   Google Scholar
• Mellins CA, Brackis-Cott E, Leu CS, et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry. 2009;50(9): 1131–1138.
   PubMed Web of Science ®Google Scholar
• Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44(6):548–556.
   Web of Science ®Google Scholar
• Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679–685.
   PubMed Web of Science ®Google Scholar
• Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opin Pharmacother. 2006;7(14):1871–1885.
   Web of Science ®Google Scholar
• US Food and Drug Administration: FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal. FDA News, 2006 Oct 6. Available from: http://www.fda.gov/bbs/topics/news/2006/new01485.html. Accessed May 1, 2010.
   Google Scholar
• US Food and Drug Administration: FDA Approves Risperdal for Two Psychiatric Conditions in Children and Adolescents. FDA News, 2007 Aug 22. Available from: http://www.fda.gov/bbs/topics/news/2007/NEW01686.html. Accessed May 1, 2010.
   Google Scholar
• Kuehn BM. FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. JAMA. 2009;302(8):833–834.
   Web of Science ®Google Scholar
• Fraguas D, Merchán-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008;69(7):1166–1175.
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008; 165(11):1420–1431.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773.
   PubMed Web of Science ®Google Scholar
• Chernoff M, Nachman S, Williams P, et al. Mental health treatment patterns in perinatally HIV-infected youth and controls. Pediatrics. 2009;124(2):627–636.
   PubMed Web of Science ®Google Scholar
• Worm SW, Friis-Møller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24(3):427–435.
   PubMed Web of Science ®Google Scholar
• Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J; for the International Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2008;47(5):607–614.
   Web of Science ®Google Scholar
• Sirois PA, Montepiedra G, Kapetanovic S, et al. Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. J Dev Behav Pediatr. 2009;30(5):403–412.
   Web of Science ®Google Scholar
• Best BM, Letendre SL, Rossi SS, et al. Low exposure to paroxetine and sertraline, but not to citalopram, escitalopram or fluoxetine in HIV-infected patients. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; 2007.
   Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–526.
   PubMed Web of Science ®Google Scholar
• Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychoticsinduced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20:368–378.
   PubMedGoogle Scholar
• Le Hellard S, Theisen FM, Haberhausen M, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry. 2009;14(3):308–317.
   PubMed Web of Science ®Google Scholar
• Ferno J, Raeder MB, Vik-Mo AO, et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics. 2005;5:298–304.
   Web of Science ®Google Scholar
• Kim JY, Zaoutis T, Chu J, Zhao H, Rutstein R. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):589–594.
   Web of Science ®Google Scholar
• Kapetanovic S, Aaron L, Montepiedra G, et al. The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV. AIDS Patient Care STDS. 2009;23(11):939–947.
   Web of Science ®Google Scholar
• Newman W, Freedman D, Voors A, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med. 1986;314:138–144.
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendations statement. Pediatrics. 2007;120:e215–e219.
   PubMed Web of Science ®Google Scholar